wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33422543-1C2F0B72-6767-43A3-AC1B-DED0DCD4C333
Q33422543-1C2F0B72-6767-43A3-AC1B-DED0DCD4C333
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33422543-1C2F0B72-6767-43A3-AC1B-DED0DCD4C333
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
P2860
Q33422543-1C2F0B72-6767-43A3-AC1B-DED0DCD4C333
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33422543-1C2F0B72-6767-43A3-AC1B-DED0DCD4C333
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7648ec58972b10d079a956aa475b8a745f5ebffb
P2860
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study.